HomeNewsTrendsHealthIndia's vaccinations fall from peak as infections hit record

India's vaccinations fall from peak as infections hit record

Vaccinations peaked at 4.5 million doses on April 5 but have averaged about 3 million a day since then, according to the government's Co-Win portal to coordinate immunisations.

April 16, 2021 / 15:02 IST
Source: Reuters

India's daily COVID-19 vaccinations have slowed from their record high early this month while new infections have set a record in eight of the past nine days, government data show, underscoring a lack of doses in the country.

After giving and selling tens of millions of COVID-19 vaccine doses abroad, India has suddenly found itself short of shots. It has abruptly changed rules to allow it to fast-track vaccine imports, having earlier rebuffed foreign drugmakers like Pfizer.

Also Read: Help increase COVID-19 vaccine production, lift embargo on raw materials, Adar Poonawalla asks US President Biden

Vaccinations peaked at 4.5 million doses on April 5 but have averaged about 3 million a day since then, according to the government's Co-Win portal to coordinate immunisations.

Follow our LIVE blog for latest updates of the novel coronavirus pandemic

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The country of 1.35 billion people has reported the most number of coronavirus cases in the world this month, flooding hospitals with patients and filling crematoriums and cemeteries with the dead. Its caseload has widened to 14.3 million, the most after the United States, with 174,308 deaths.

The ferocious second surge, which overtook the pace of the first in a matter of weeks, had sent people rushing to vaccination centres, but many centres are now rationing supplies as output fails to meet demand.

India is vaccinating only people aged above 45 years, having started the campaign in the middle of January with health and then other front-line workers. It has so far administered 115.5 million doses, the most in the world after the United States and China, though it ranks much lower when accounting for population.

Many states have sought an expansion of the inoculation drive to include all adults as cases rise, but the government has said doses are "finite", although enough to cover the identified groups.

The government said on Friday the country had a stock of about 30 million doses. Going by India's immunisation trend in the past week, that will be enough to last 10 days.

As supplies tighten, India this week gave emergency authorisation to Russia's Sputnik V vaccine and imports to cover as many as 125 million people will start this month.

The government has also urged Pfizer, Moderna and Johnson and Johnson to sell their shots to India and has made rules easier for them.

India has also allowed biomedical research body Haffkine Institute, based in the western state of Maharashtra, to produce the home-grown shot Covaxin as developer Bharat Biotech struggles to boost its output.

The AstraZeneca vaccine, locally made by the Serum Institute of India (SII), accounts for more than 91 percent of total doses given in the country. Production ramp-up at SII, the world's biggest vaccine maker, has been delayed by a raw-material shortage.

Follow our full coverage of the coronavirus pandemic here.

Reuters
first published: Apr 16, 2021 02:50 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347